<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819620</url>
  </required_header>
  <id_info>
    <org_study_id>PN-232-01</org_study_id>
    <nct_id>NCT04819620</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of PN-232 in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-controlled Study of Single and Multiple Ascending Doses of PN-232 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protagonist Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protagonist Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is designed to determine the safety, tolerability and pharmacokinetics of&#xD;
      PN-232 in healthy volunteers. It is a first-in-human (FIH) study for PN-232 that will be&#xD;
      conducted in three parts. Part 1 is a single ascending dose study, Part 2 is multiple&#xD;
      ascending dose study, and Part 3 is crossover solid dose comparison and effect of food study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Approximately 32 subjects will be enrolled into 4 cohorts to receive PN-232 or&#xD;
      placebo as single doses.&#xD;
&#xD;
      Part 2: Up to 40 subjects will be enrolled into 4 cohorts to receive PN-232 or placebo once&#xD;
      daily for 10 days.&#xD;
&#xD;
      Part 3: Twelve subjects will receive single doses of PN-232 in a 3-way, randomized, crossover&#xD;
      fashion.&#xD;
&#xD;
      In total, approximately 84 subjects will participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PN-232</measure>
    <time_frame>10 days</time_frame>
    <description>Number and Severity of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentration of PN-232 in plasma</measure>
    <time_frame>10 days</time_frame>
    <description>Peak concentration (Cmax) of PN-232</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Concentration (AUC) of PN-232</measure>
    <time_frame>10 days</time_frame>
    <description>AUC over 24 hours on Day 10 for PN-232</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid Dose Comparison</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solid dose administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN-232</intervention_name>
    <description>Active Drug</description>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_label>Solid Dose Comparison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have BMI between 18 and 32 kg/m2&#xD;
&#xD;
          -  Subjects must be non-smokers or social smokers&#xD;
&#xD;
          -  Subjects must comply with contraception requirements&#xD;
&#xD;
          -  Subjects must be willing to consume meals provided by the clinical center&#xD;
&#xD;
          -  Subjects must be willing to attend required clinic visits&#xD;
&#xD;
          -  Subjects must be suitable candidates for study procedures&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a history of clinically significant endocrine, neurological,&#xD;
             cardiovascular, hematological, hepatic, immunological, renal, respiratory,&#xD;
             gastrointestinal or genitourinary abnormalities or diseases within previous 10 years&#xD;
&#xD;
          -  Subjects with a history of surgical resection of the stomach, small or large intestine&#xD;
&#xD;
          -  Subjects with a fever or symptomatic viral or bacterial infection within 2 weeks of&#xD;
             screening or intestinal infection within 30 days prior to screening&#xD;
&#xD;
          -  Subjects with clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Subjects with corrected QT greater than 450 msec in males and 470 msec in females&#xD;
&#xD;
          -  Subjects who test positive for Hepatitis C or B, or HIV at Screening&#xD;
&#xD;
          -  Subjects who cannot refrain from use of prescription and non-prescription drugs and&#xD;
             herbal remedies prior to initial dose of study drug and throughout the study&#xD;
&#xD;
          -  Subjects who test positive for drugs of abuse or alcohol at Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>1-888-899-1543</phone>
    <email>ptgxclinicaltrials@ptgx-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Protagonist Clinical Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Protagonist Study Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

